US › Healthcare

Kezar Life Sciences Inc (KZR)

US · Healthcare · Biotechnology

$0.140.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Net profit
$-5.8M
Profit YoY
+65.2%
EPS
$-0.70
EPS estimate
$-0.98

EPS came in at -0.70 against a street estimate of -0.98 — a beat of 28.5%.

Key statistics

Market cap
$53.9M
Forward P/E
0.0
P/B
0.77
Book value
$9.56
EPS (TTM)
$-6.17
52-week high
$7.55
52-week low
$0.12
50-day MA
$7.14
200-day MA
$5.87
Beta
0.41

Analyst view

Analysts rate Kezar Life Sciences Inc a buy (3 buy, 3 hold, 0 sell out of 6) with an average price target of $6.00.

Shareholding

Insiders
15.78%
Institutions
61.26%

Largest institutional holders

FundStake
BML Capital Management LLC9.76%
Suvretta Capital Management, LLC9.70%
TANG CAPITAL MANAGEMENT LLC8.99%
Vanguard Capital Management, LLC3.93%
Affinity Asset Advisors, LLC3.10%
Renaissance Technologies Corp2.55%
Acadian Asset Management LLC2.05%
Millennium Management LLC1.92%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kezar Life Sciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.